Investor Information

Founded in 2017, Amplitude Vascular Systems (AVS) is an early-stage medical device company that is focused on safely and effectively treating severely calcified arterial disease. AVS is the first company to develop PULSE IVL™, a device that delivers intravascular lithotripsy treatment through a balloon-based platform. It is designed to be the only minimally invasive technology that gently shatters calcium and opens the artery using a single device.

Upcoming Events

TCT 2023 MedTech Innovation Forum - October 23, 2023 - October 26, 2023

Moscone Center San Francisco, CA TCT 2023 (crfconnect.com)

VIVA - Vascular Interventional Advances Forum - October 30, 2023 - November 2, 2023

Wynn Las Vegas Attend VIVA | VIVA (viva-foundation.org)

Investor Publications

We are committed to working with leading interventionalists to publish study data that supports the value of PULSE IVL™ for the treatment of severely calcified vessels.

Venture Interest in Medical Devices Holds Up, But Investors Are Choosy
Digital health news, funding round up in the prior week; January 9, 2023
Fidelity is writing down its Twitter investment—will Sequoia and a16z be next?
AVS Rakes in $20M to Advance Plaque-shattering Arterial Disease Treatment
AVS Raises $20M in Series B Funding Round
AVS Raises Financing to Advance Its Pulsatile Intravascular Lithotripsy Solutions